Investigating how PDK2 affects heart failure through metabolic and genetic changes
Official title: Novel roles of PDK2 in heart failure: Regulation of mitochondrial nuclear crosstalk via metabolic regulation and histone acetylation
Funded at University of Alabama at Birmingham · NIH-11047706 · Data updated 2026-11-12
This study is looking at a protein called PDK2 to see how it affects the heart's ability to use sugar for energy, which could help us understand heart failure better and find new ways to improve heart health for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Alabama at Birmingham NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project start | April 1, 2023 |
| Project end | March 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $417,024 |
| NIH project number | 5R01HL167872-03 |
| Project ID | NIH-11047706 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults over 21 years old who are experiencing heart failure or related cardiac conditions.
✕Less likely to help
Patients with heart conditions unrelated to metabolic regulation or those under 21 years old may not benefit from this research.
What this research studies
This research focuses on understanding the role of a specific protein, PDK2, in heart failure. It examines how PDK2 influences the heart's ability to use glucose for energy and how this process is affected by various physiological and pathological conditions. By studying animal models, the researchers aim to uncover the molecular mechanisms behind heart failure and explore potential therapeutic interventions that could improve heart function. Patients may benefit from insights gained about metabolic regulation in heart disease.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that improve heart function and outcomes for patients with heart failure.
How similar studies have gone: Previous research has shown promising results in targeting metabolic pathways in heart disease, suggesting that this approach could lead to significant advancements.
Where this research is happening
-
University of Alabama at Birmingham
Birmingham, United States Active
Researchers
- Principal investigator: Wende, Adam Raymond — University of Alabama at Birmingham
- Study coordinator: Wende, Adam Raymond
Related research
Other NIH-funded projects on the same topics.
-
AI-supported heart failure diagnosis and management in Rwanda
Aiming to help people with suspected heart failure in Rwanda get faster, more accurate diagnoses and better care using AI-guided ultrasound and care protocols.
-
AI-assisted heart failure diagnosis in Rwanda using focused ultrasound
An NIH-funded project will test whether AI-enhanced, easy-to-use heart ultrasound can help non-experts diagnose and manage heart failure in Rwanda.
-
HF endotypes in heart failure using ethical multi-modal AI and molecular data
A patient-friendly project that uses advanced AI and multiple kinds of health data to identify distinct heart failure subtypes that could guide personalized care.
-
Triple gene therapy approach to heal the heart after a heart attack
A new therapy combines three genetic approaches delivered by a virus to help the heart heal after a heart attack.
-
Digital-first heart failure care delivery in Uganda
A targeted program in Uganda tests a digital care plan to help people with heart failure manage their symptoms at home.
-
Digital-first heart failure care delivery in Uganda
A study to test digital self-care tools to help people with heart failure in Uganda manage symptoms and stay healthier.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.